Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Silence Therapeutics
Silence Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Bevel edge or radius edge flat face tablets: Which is better for greater consumer acceptance?
Consumers and patients should perceive that their tablets are easy to swallow and devoid of any undesirable taste. Tablet manufacturers can influence acceptance of by producing...
The (r)evolution of biocatalysis in API synthesis
Explore Farmhispania Group’s enzyme toolbox to develop cost-effective, green-by-design synthetic routes for the cGMP production of your small-molecule NCEs
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all
Related Content
Ingredients
AstraZeneca joins forces with Silence to develop siRNA therapeutics
Collaboration with Silence Therapeutics has been agreed to develop small interfering RNA therapeutics that act inside the cell to influence protein production
New CEO at Silence Therapeutics
Recruitment
Silence Therapeutics announces leadership change
Recruitment
Appointment of Dr Annalisa Jenkins as non-executive Chair
Regulatory
Silence strengthens US patent estate
Silence Therapeutics, developers of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced a further key US patent 9,695,423 has been granted to Silence this month
Pharmaceutical
Silence Therapeutics names Chief Operating Officer
Recruitment
Silence Therapeutics appoints Dmitry Samarsky as Chief Scientific Officer and Dr Andy Richards as Non-Executive Director
Silence's technology harnesses the body’s natural mechanisms to create therapeutic effects within its cells
Subscribe now